About Lung News Today

Media Release Immuno-oncology combination of eftilagimod alpha and the leading anti-PD-1 therapy generates meaningful long-term survival in non-small cell lung cancer patients in Phase II TACTI-002... | May 17, 2023

 Phase III CANOPY-A trial did not meet primary endpoint of disease-free survival in patients with stages II-IIIA and IIIB completely resected non-small...

Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer

/PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced the release...

/PRNewswire/ -- Novartis today announced the first published mature overall survival (OS) and updated overall response rate (ORR) data following treatment with...

Tabrecta (capmatinib) showed a median overall survival (OS) of 20.8 months in treatment-naïve patients and 13.6 months in previously-treated patients in first published mature data1,2 Tabrecta achieved

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

Novartis Pharma AG: Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer 1 non-small cell lung cancer 2,3 help 1 beta (IL-1ß) in pro-tumor inflammation i n lung cancer, with multiple clinical trials investigating canakinumab in 2 -5 Basel, March 9, 2021 - Novartis announced today the Phase III CANOPY-2 study evaluating canakinumab (ACZ885), an inhibitor of interleukin-1b...

19. More people die of lung cancer every year than any other cancer type 11. Novartis is committed to developing best-in-class treatments for lung cancer patients around the world. With a focus on both targeted, personalized medicine and the role of newer, immuno-oncology therapies, the lung cancer drug development program at Novartis is among the most robust in the industry. With research activities informed by long-term relationships with leading lung cancer thought leaders and patient adv...

Press release content from Business Wire. The AP news staff was not involved in its creation. HERTHENA-Lung01 Phase 2 Study of Daiichi Sankyo’s Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated NSCLC February 3, 2021 GMT TOKYO & BASKING RIDGE, N.J. & MUNICH--(BUSINESS WIRE)--Feb 3, 2021-- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the first patient has been dosed in HERTHENA-Lung01, a phase 2 study evaluating patritumab deruxtecan, a HER3 dire...